ESLA Q2 2023 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$169,240

Net Income

-$76,004

EPS (Diluted)

$-0.03

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$212,666

Free Cash Flow

-$212,666

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$10M

Total Liabilities

$3M

Stockholders' Equity

$7M

Cash & Equivalents

$34,688

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$169,240	-$1M	+84.2%
Net Income	-$76,004	-$1M	+92.9%